Cystatin C is an emerging biomarker that enhances kidney function assessment accuracy, particularly in hospitalized patients ...
Aumolertinib had comparable efficacy to osimertinib when treating epidermal growth factor receptor ( EGFR )-mutant non-small ...
Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients ...
First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). Among a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback